Investigators identify clinical and neuroimaging markers associated with the presence of cortical superficial siderosis and the risk for recurrent ICH.
An inverse relationship was discovered between rising cholesterol levels and decreased risk for intracerebral hemorrhage in new statin users.
Patients with intracerebral hemorrhage who were admitted to acute stroke units were randomly assigned to either 1 gram intravenous tranexamic acid followed by an 8-hour infusion of 1 gram tranexamic acid or matched placebo.
While developing the hematoma expansion prediction score, associations between hematoma expansion and blend sign, any intrahematoma hypodensity, and time from onset to noncontrast computed tomography <2.5 hours were found.
Investigators performed a pre-planned secondary analysis of the open-label, randomized Antihypertensive Treatment of Acute Cerebral Hemorrhage 2 study, specifically on the magnetic resonance images obtained during the intensive blood pressure lowering portion of the trial.
The investigators of this study did not compare pre- or post-hemorrhage data, precluding their ability to determine the applicability of the findings for improving clinical practice.
Investigators conducted a meta-analysis of trials that reported functional outcomes and mortality rates among patients with intracerebral hemorrhage following intensive blood pressure lowering.
Further research may be necessary to better understand the pathophysiologic mechanisms involved in perihemorrhagic edema evolution and ICH.
For patients with CKD and atrial fibrillation, anticoagulants are linked with an increased risk of ischemic stroke.
Outcomes in intracerebral hemorrhage are less severe in patients with prior NOAC use.
Results from a secondary analysis of the ENCHANTED trial add to a pile of weak data that likely will not affect clinical practice.
Surprisingly, no evidence was found to suggest that patients with these markers benefit from intensive blood pressure reduction.
Intensive antiplatelet therapy appears to reduce risk of recurrence immediately after stroke, but may pose risks further out.
Resumption of oral anticoagulants after intracerebral hemorrhage was found to improve outcomes at 1 year.
The investigators reported no difference in 3-month mortality rates across all 5 studies included in the meta-analysis.
Restarting anticoagulation after both nonlobar and lobar ICH was associated with decreased mortality.
As more patients survive ICH, emphasis is slowly shifting from survival to improving ICH-related morbidity and optimization of functional recovery.
Optimal antiplatelet treatment has yet to be determined for stroke survivors with prior intracerebral hemorrhage.
Among ICH survivors, 63% developed both depression and dementia during a 5-year follow-up study.
Recent research found benefits in outcome outweighed any increase in hemorrhagic complications in patients with large infarcts.
Notably, the location of ICH influenced the association with hematoma volume and growth in patients with prior antiplatelet use.
Cerebral microbleeds increase the risk for symptomatic ICH after thrombolysis for acute ischemic stroke.
Lower serum calcium levels correlate with risk of hematoma expansion in intracerebral hemorrhage.
Risk factors differ for early vs late-onset dementia after ICH.
A joint medical and surgical approach may ensure the best outcome.
Neurology Advisor Articles
- OCD in Duchenne Muscular Dystrophy Features Distinct Phenotype, Associated Symptoms
- History of Migraine Associated With Higher Risk for Cochlear Disorders
- Patent Foramen Ovale Closure for Stroke Prevention: Key Principles for Clinical Practice
- Vagus Nerve Stimulation in Pediatric Epilepsy: Weighing the Risks and Benefits
- A Model for Predicting Quality of Life Improvements After Deep Brain Stimulation
- Some Statins May Be Associated With Cognition, Memory Deficits
- Neuropathic Pain Treatments
- Cannabis for Multiple Sclerosis: Prescriber's Perspective
- New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's
- Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications
- Apomorphine Infusions Improves Off Time Associated With Parkinson Disease
- FDA Grants Orphan Drug Status to Angelman Syndrome Treatment
- Treatment of New-Onset Epilepsy: AAN, AES Update Practice Guidelines
- Clinical, Radiologic Markers Predictive of Cortical Superficial Siderosis in ICH Identified
- Migraine Pain Location May Not Have Clinical Implications